I don’t know if they do it, because no independent researchers examine those swabs, but I have always pointed out that our overlords seem more concerned with testing than with vaccinating. Almost like the vaccines were the bait and tests were the switch. And now we also know they totally CAN do that.
Just follow the science below.

UPDATE: LMAO, THIS WENT SO VIRAL VICE WAS SENT TO DEBUNK IT, SEE FOR YOURSELF, IT’S HILARIOUS!

UPDATE: DR. LORRAINE DAY QUOTES AND FURTHER EXPLAINS THIS VERY ARTICLE!

November 3, 2020

Researchers engineer tiny machines that deliver medicine efficiently

by Johns Hopkins University School of Medicine

Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.

David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.

Made of metal and thin, shape-changing film and coated in a heat-sensitive paraffin wax, “theragrippers,” each roughly the size of a dust speck, potentially can carry any drug and release it gradually into the body.

The team published results of an animal study this week as the cover article in the journal Science Advances.

Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.

“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”

Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.

Gracias notes advances in the field of biomedical engineering in recent years.

“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”

Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”

The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.

---

At this point I just need to recall our October 2020 article: FACT-CHECKERS LIE: TEST SWABS REALLY LIKELY TO GIVE YOU THE “LEAKY BRAIN”

HERE’S A VERY SIMPLE WAY TO ATTACK THE BRAIN THROUGH THE TEST SWABS

I’ve seen a report on someone who had to undergo tests almost daily and he developed brain cancer over the course of about three months. But I can’t verify it, so that’s all it’s worth.

SPOOKY FIBERS IN MAKS AND TEST SWABS? WAIT ’TIL YOU READ THE SCIENCE!

Aaaand the last piece of the puzzle that we needed to get the picture. We may have missed many details, but we got the core idea right:

“Key to our findings is the demonstration that S1 promotes loss of barrier integrity in an advanced 3D microfluidic model of the human BBB, a platform that more closely resembles the physiological conditions at this CNS interface. Evidence provided suggests that the SARS-CoV-2 spike proteins trigger a pro-inflammatory response on brain endothelial cells that may contribute to an altered state of BBB function. Together, these results are the first to show the direct impact that the SARS-CoV-2 spike protein could have on brain endothelial cells; thereby offering a plausible explanation for the neurological consequences seen in COVID-19 patients.”

Report contents include:

• Market analysis of nano-based diagnostic tests for COVID-19 including nanosensors incorporating gold nanoparticles, iron oxide nanoparticles, graphene, quantum dots, carbon quantum dots and carbon nanotubes. Market revenues adjusted to pandemic outcomes. In-depth company profiles. Companies profiled include Abbott Laboratories, Cardea, Ferrotec (USA) Corporation, E25Bio, Grolltex, Inc., Luminex Corporation etc.

More info here: A DIVERSITY OF NANOTECH 100% CONFIRMED IN COVID TESTS, MASKS, INJECTIONS AND A WIDE RANGE OF PRODUCTS

Application of Nanotechnology in the COVID-19 Pandemic

Dongki Yang¹

Internationa Journal of Nanomedicine. 2021; 16: 623–649.
Published online 2021 Jan 26. 
doi: 10.2147/IJN.S296383

Intranasal Delivery Therapy

Currently, many studies are being conducted on developing a method for delivering nanoparticles into the nasal cavity as a safe and more effective countermeasure against viral infection and treatment.¹⁸⁰ Since SARS-CoV-2 initiates infection on the mucosal surface of the eye or nasal cavity, mucosal therapy is the most important strategy for treating such infectious diseases. Delivery through the nasal cavity is not only simple and inexpensive but also non-invasive, and the NP is rapidly absorbed due to the cavity’s abundant capillary plexus and large surface area.¹⁸¹ The properties of the NPs, such as the surface charge, size, and shape, are important factors to be considered while optimizing the method of delivery to the nasal cavity and play a critical role in effective and safe treatment.¹⁸² Studies have been conducted using small animals to evaluate the system that is delivered to the lungs by administering NPs to the nasal cavity. Therefore, findings of these animal studies cannot be easily generalized to humans. To date, three types of NPs (organic, inorganic, and virus-like NPs) have been designed with delivery capabilities that are suitable for therapeutic purposes, which can also be administered intranasally for effective delivery.

Nasal-nanotechnology: revolution for efficient therapeutics delivery

Amrish Kumar ¹, Aditya Nath Pandey ¹, Sunil Kumar Jain ¹

Drug Delivery 2016;  Epub 2014 Jun 5.

Abstract

Context: In recent years, nanotechnology-based delivery systems have gained interest to overcome the problems of restricted absorption of therapeutic agents from the nasal cavity, depending upon the physicochemical properties of the drug and physiological properties of the human nose.

Objective: The well-tolerated and non-invasive nasal drug delivery when combined with the nanotechnology-based novel formulations and carriers, opens the way for the effective systemic and brain targeting delivery of various therapeutic agents. To accomplish competent drug delivery, it is imperative to recognize the interactions among the nanomaterials and the nasal biological environment, targeting cell-surface receptors, drug release, multiple drug administration, stability of therapeutic agents and molecular mechanisms of cell signaling involved in patho-biology of the disease under consideration.

Methods: Quite a few systems have been successfully formulated using nanomaterials for intranasal (IN) delivery. Carbon nanotubes (CNTs), chitosan, polylactic-co-glycolic acid (PLGA) and PLGA-based nanosystems have also been studied in vitro and in vivo for the delivery of several therapeutic agents which shown promising concentrations in the brain after nasal administration.

Results and conclusion: The use of nanomaterials including peptide-based nanotubes and nanogels (NGs) for vaccine delivery via nasal route is a new approach to control the disease progression. In this review, the recent developments in nanotechnology utilized for nasal drug delivery have been discussed.

Keywords: Intranasal; nano-delivery systems; nasal vaccination; non-invasive; nose-to-brain delivery.

Similar articles

• Nanoparticles for direct nose-to-brain delivery of drugs.Mistry A, Stolnik S, Illum L.Int J Pharm. 2009 Sep 8;379(1):146-57. doi: 10.1016/j.ijpharm.2009.06.019. Epub 2009 Jun 23.PMID: 19555750 Review.
• Nanotechnology-based drug delivery systems.Suri SS, Fenniri H, Singh B.J Occup Med Toxicol. 2007 Dec 1;2:16. doi: 10.1186/1745-6673-2-16.PMID: 18053152 Free PMC article.
• Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery.Alshweiat A, Ambrus R, Csoka I.Curr Med Chem. 2019;26(35):6459-6492. doi: 10.2174/0929867326666190827151741.PMID: 31453778 Review.
• Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.Gonçalves VSS, Matias AA, Poejo J, Serra AT, Duarte CMM.Int J Pharm. 2016 Dec 30;515(1-2):1-10. doi: 10.1016/j.ijpharm.2016.09.086. Epub 2016 Oct 1.PMID: 27702697

Inhaled nanoparticles–a current review

Wei Yang ¹, Jay I Peters, Robert O Williams 3rd

International Journal of Pharmaceutics 2008 May 22;

Abstract

The field of nanotechnology may hold the promise of significant improvements in the health and well being of patients, as well as in manufacturing technologies. The knowledge of this impact of nanomaterials on public health is limited so far. This paper briefly reviews the unique size-controlled properties of nanomaterials, their disposition in the body after inhalation, and the factors influencing the fate of inhaled nanomaterials. The physiology of the lung makes it an ideal target organ for non-invasive local and systemic drug delivery, especially for protein and poorly water-soluble drugs that have low oral bioavailability via oral administration. The potential application of pulmonary drug delivery of nanoparticles to the lungs, specifically in context of published results reported on nanomaterials in environmental epidemiology and toxicology is reviewed in this paper.

Nanoparticles for nasal vaccination

Noemi Csaba ¹, Marcos Garcia-Fuentes, Maria Jose Alonso

Advanced Drug Delivery Review. 
2009 Feb 27; doi: 10.1016/j.addr.2008.09.005. Epub 2008 Dec 13.

Abstract

The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.

Similar articles

• Nanoparticles as carriers for nasal vaccine delivery. Köping-Höggård M, Sánchez A, Alonso MJ.Expert Rev Vaccines. 2005 Apr;4(2):185-96. doi: 10.1586/14760584.4.2.185.PMID: 15889992 Review.
• Nasal delivery of vaccines. Almeida AJ, Alpar HO.J Drug Target. 1996;3(6):455-67. doi: 10.3109/10611869609015965.PMID: 8863138 Review.
• Nanoparticles and microparticles as vaccine-delivery systems. Singh M, Chakrapani A, O’Hagan D.Expert Rev Vaccines. 2007 Oct;6(5):797-808. doi: 10.1586/14760584.6.5.797.PMID: 17931159 Review.
• Nasal vaccine innovation. Jabbal-Gill I.J Drug Target. 2010 Dec;18(10):771-86. doi: 10.3109/1061186X.2010.523790.PMID: 21047271 Review.
• Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. Sharma S, Mukkur TK, Benson HA, Chen Y.J Pharm Sci. 2009 Mar;98(3):812-43. doi: 10.1002/jps.21493.PMID: 18661544 

---

Check the follow ups in the Bio-hacking trilogy:

RNA MODIFICATION USED TO ALTER DNA, BRAIN FUNCTIONS AND BEHAVIOR
Part 3 went straight to video:
THE WALKING SERVERS. DON’T BE ONE, LEARN ABOUT DNA STORAGE, DNA PRIVACY AND BIOHACKING – DOCUMENTARY

Epub 2008 Dec 13.

Nanoparticles for nasal vaccination

Noemi Csaba  ¹ , Marcos Garcia-Fuentes, Maria Jose Alonso

• PMID: 19121350
• DOI: 10.1016/j.addr.2008.09.005

Abstract

The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.

---

Similar articles

• Nanoparticles as carriers for nasal vaccine delivery. Köping-Höggård M, Sánchez A, Alonso MJ. Expert Rev Vaccines. 2005 Apr;4(2):185-96. doi: 10.1586/14760584.4.2.185. PMID: 15889992
• Nasal delivery of vaccines. Almeida AJ, Alpar HO. J Drug Target. 1996;3(6):455-67. doi: 10.3109/10611869609015965. PMID: 8863138 Review.
• Nanoparticles and microparticles as vaccine-delivery systems. Singh M, Chakrapani A, O’Hagan D. Expert Rev Vaccines. 2007 Oct;6(5):797-808. doi: 10.1586/14760584.6.5.797. PMID: 17931159
• Nasal vaccine innovation. Jabbal-Gill I. J Drug Target. 2010 Dec;18(10):771-86. doi: 10.3109/1061186X.2010.523790. PMID: 21047271
• Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. Sharma S, Mukkur TK, Benson HA, Chen Y. J Pharm Sci. 2009 Mar;98(3):812-43. doi: 10.1002/jps.21493. PMID: 18661544

PubMed, 2015 Jun 9.:

Nanoneurotherapeutics approach intended for direct nose to brain delivery

Shadab Md  ¹ , Gulam Mustafa  ^{2   3} , Sanjula Baboota  ³ , Javed Ali  ³ Affiliations Expand

• PMID: 26057769
• DOI: 10.3109/03639045.2015.1052081

Abstract

Context: Brain disorders remain the world’s leading cause of disability, and account for more hospitalizations and prolonged care than almost all other diseases combined. The majority of drugs, proteins and peptides do not readily permeate into brain due to the presence of the blood-brain barrier (BBB), thus impeding treatment of these conditions.

Objective: Attention has turned to developing novel and effective delivery systems to provide good bioavailability in the brain.

Methods: Intranasal administration is a non-invasive method of drug delivery that may bypass the BBB, allowing therapeutic substances direct access to the brain. However, intranasal administration produces quite low drug concentrations in the brain due limited nasal mucosal permeability and the harsh nasal cavity environment. Pre-clinical studies using encapsulation of drugs in nanoparticulate systems improved the nose to brain targeting and bioavailability in brain. However, the toxic effects of nanoparticles on brain function are unknown.

Result and conclusion: This review highlights the understanding of several brain diseases and the important pathophysiological mechanisms involved. The review discusses the role of nanotherapeutics in treating brain disorders via nose to brain delivery, the mechanisms of drug absorption across nasal mucosa to the brain, strategies to overcome the blood brain barrier, nanoformulation strategies for enhanced brain targeting via nasal route and neurotoxicity issues of nanoparticles.

Epub 2013 Oct 16.

Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting

Hitendra S Mahajan  ¹ , Milind S Mahajan, Pankaj P Nerkar, Anshuman Agrawal Affiliations Expand

• PMID: 24128122
• DOI: 10.3109/10717544.2013.838014

Abstract

The central nervous system (CNS) is an immunological privileged sanctuary site-providing reservoir for HIV-1 virus. Current anti-HIV drugs, although effective in reducing plasma viral levels, cannot eradicate the virus completely from the body. The low permeability of anti-HIV drugs across the blood-brain barrier (BBB) leads to insufficient delivery. Therefore, developing a novel approaches enhancing the CNS delivery of anti-HIV drugs are required for the treatment of neuro-AIDS. The aim of this study was to develop intranasal nanoemulsion (NE) for enhanced bioavailability and CNS targeting of saquinavir mesylate (SQVM). SQVM is a protease inhibitor which is a poorly soluble drug widely used as antiretroviral drug, with oral bioavailability is about 4%. The spontaneous emulsification method was used to prepare drug-loaded o/w nanoemulsion, which was characterized by droplet size, zeta potential, pH, drug content. Moreover, ex-vivo permeation studies were performed using sheep nasal mucosa. The optimized NE showed a significant increase in drug permeation rate compared to the plain drug suspension (PDS). Cilia toxicity study on sheep nasal mucosa showed no significant adverse effect of SQVM-loaded NE. Results of in vivo biodistribution studies show higher drug concentration in brain after intranasal administration of NE than intravenous delivered PDS. The higher percentage of drug targeting efficiency (% DTE) and nose-to-brain drug direct transport percentage (% DTP) for optimized NE indicated effective CNS targeting of SQVM via intranasal route. Gamma scintigraphy imaging of the rat brain conclusively demonstrated transport of drug in the CNS at larger extent after intranasal administration as NE.

Similar articles

• Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Int J Pharm. 2008 Jun 24;358(1-2):285-91. doi: 10.1016/j.ijpharm.2008.03.029. Epub 2008 Mar 27. PMID: 18455333
• Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. AAPS PharmSciTech. 2006 Jan 20;7(1):E8. doi: 10.1208/pt070108. PMID: 16584167
• Nanoneurotherapeutics approach intended for direct nose to brain delivery. Md S, Mustafa G, Baboota S, Ali J. Drug Dev Ind Pharm. 2015;41(12):1922-34. doi: 10.3109/03639045.2015.1052081. Epub 2015 Jun 9. PMID: 26057769 Review.
• Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. Shinde RL, Bharkad GP, Devarajan PV. Eur J Pharm Biopharm. 2015 Oct;96:363-79. doi: 10.1016/j.ejpb.2015.08.008. Epub 2015 Aug 28. PMID: 26318978
• Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Int J Pharm. 2019 Jun 30;565:258-268. doi: 10.1016/j.ijpharm.2019.05.032. Epub 2019 May 13. PMID: 31095983 Review.

PubMed Epub, 2016 Jun 28:

Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery

Sara Salatin  ^{1   2} , Jaleh Barar  ^{1   3} , Mohammad Barzegar-Jalali  ³ , Khosro Adibkia  ^{3   4} , Mitra Alami Milani  ^{2   4} , Mitra Jelvehgari  ^{5   6} Affiliations Expand

Affiliations

• ¹ Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Science, Tabriz, Iran.
• ² Student Research Committee, Tabriz University of Medical Science, Tabriz, Iran.
• ³ Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Mailbox 51664, Tabriz, Iran.
• ⁴ Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
• ⁵ Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Mailbox 51664, Tabriz, Iran. mitra_jelvehgari@yahoo.com.
• ⁶ Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. mitra_jelvehgari@yahoo.com.

• PMID: 27352214
• DOI: 10.1007/s12272-016-0782-0

Abstract

Over the past few years, nasal drug delivery has attracted more and more attentions, and been recognized as the most promising alternative route for the systemic medication of drugs limited to intravenous administration. Many experiments in animal models have shown that nanoscale carriers have the ability to enhance the nasal delivery of peptide/protein drugs and vaccines compared to the conventional drug solution formulations. However, the rapid mucociliary clearance of the drug-loaded nanoparticles can cause a reduction in bioavailability percentage after intranasal administration. Thus, research efforts have considerably been directed towards the development of hydrogel nanosystems which have mucoadhesive properties in order to maximize the residence time, and hence increase the period of contact with the nasal mucosa and enhance the drug absorption. It is most certain that the high viscosity of hydrogel-based nanosystems can efficiently offer this mucoadhesive property. This update review discusses the possible benefits of using hydrogel polymer-based nanoparticles and hydrogel nanocomposites for drug/vaccine delivery through the intranasal administration.

Keywords: Brain; Hydrogel; Nanoparticles; Nasal delivery; Vaccine.

Similar articles

• Nanoparticles for nasal vaccination. Csaba N, Garcia-Fuentes M, Alonso MJ.Csaba N, et al.Adv Drug Deliv Rev. 2009 Feb 27;61(2):140-57. doi: 10.1016/j.addr.2008.09.005. Epub 2008 Dec 13.Adv Drug Deliv Rev. 2009.PMID: 19121350 Review.
• Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? Illum L.Illum L.J Pharm Sci. 2007 Mar;96(3):473-83. doi: 10.1002/jps.20718.J Pharm Sci. 2007.PMID: 17117404 Review.
• Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. Sharma S, Mukkur TK, Benson HA, Chen Y.Sharma S, et al.J Pharm Sci. 2009 Mar;98(3):812-43. doi: 10.1002/jps.21493.J Pharm Sci. 2009.PMID: 18661544 Review.
• Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Mahajan HS, Mahajan MS, Nerkar PP, Agrawal A.Mahajan HS, et al.Drug Deliv. 2014 Mar;21(2):148-54. doi: 10.3109/10717544.2013.838014. Epub 2013 Oct 16.Drug Deliv. 2014.PMID: 24128122
• The application of mucoadhesive polymers in nasal drug delivery. Jiang L, Gao L, Wang X, Tang L, Ma J.Jiang L, et al.Drug Dev Ind Pharm. 2010 Mar;36(3):323-36. doi: 10.1080/03639040903170750.Drug Dev Ind Pharm. 2010.PMID: 19735210 Review.

• Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Ahmed OAA, Fahmy UA, Badr-Eldin SM, Aldawsari HM, Awan ZA, Asfour HZ, Kammoun AK, Caruso G, Caraci F, Alfarsi A, Al-Ghamdi RA, Al-Ghamdi RA, Alhakamy NA.Ahmed OAA, et al.Nanomaterials (Basel). 2020 Jun 29;10(7):1270. doi: 10.3390/nano10071270.Nanomaterials (Basel). 2020.PMID: 32610539 Free PMC article.
• Stimulus-responsive polymeric nanogels as smart drug delivery systems. Hajebi S, Rabiee N, Bagherzadeh M, Ahmadi S, Rabiee M, Roghani-Mamaqani H, Tahriri M, Tayebi L, Hamblin MR.Hajebi S, et al.Acta Biomater. 2019 Jul 1;92:1-18. doi: 10.1016/j.actbio.2019.05.018. Epub 2019 May 13.Acta Biomater. 2019.PMID: 31096042 Free PMC article. Review.
• Preparation and Property Evaluation of Conductive Hydrogel Using Poly (Vinyl Alcohol)/Polyethylene Glycol/Graphene Oxide for Human Electrocardiogram Acquisition. Xiao X, Wu G, Zhou H, Qian K, Hu J.Xiao X, et al.Polymers (Basel). 2017 Jun 30;9(7):259. doi: 10.3390/polym9070259.Polymers (Basel). 2017.PMID: 30970936 Free PMC article.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them